Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study
Open Access
- 31 January 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-9
Abstract
Background: Gliomas consist of a heterogeneous group of tumors. This study aimed to report the incidences of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation, 1p19q co-deletion, isocitrate dehydrogenase (IDH) gene mutations, and inactivating mutations of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) in high-grade gliomas in an ethnically diverse population.Methods: Records of patients who underwent surgery for high-grade gliomas from January 2013 to March 2017 at our institution were obtained. The patients’ age, gender, ethnicity, Karnofsky Performance Scale (KPS) score, ability to perform activities of daily living (ADLs), tumor location and biomarkers status were recorded. Data were analyzed using chi-square and Mann-Whitney U tests, Kaplan-Meier estimates and log-rank test.Results: 181 patients were selected (56 with grade III gliomas, 125 with grade IV gliomas). In the grade III group, 55% had MGMT promoter methylation, 41% had 1p19q co-deletion, 35% had IDH1 mutation and none had ATRX loss. In the grade IV group, 30% had MGMT promoter methylation, 2% had 1p19q co-deletion, 15% had IDH1 mutation and 8% had ATRX loss. After adjusting for effects of age, surgery and pre-operative ADL statuses, only MGMT promoter methylation was found to be significantly associated with longer overall survival time in grade III (p = 0.024) and IV patients (p = 0.006).Conclusions: The incidences of MGMT promoter methylation and IDH1 mutation were found to be comparable to globally reported rates, but those of 1p19q co-deletion and ATRX loss seemed to be lower in our cohort. MGMT promoter methylation was associated with increased overall survival in our cohort and might serve as favorable prognostic factor.Keywords
Funding Information
- National Medical Research Council (NMRC/TCR/016-NNI/2016)
This publication has 55 references indexed in Scilit:
- Personalized treatment strategies in glioblastoma: MGMT promoter methylation statusOncoTargets and Therapy, 2013
- IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-AnalysisPLOS ONE, 2013
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951Journal of Clinical Oncology, 2013
- O6‐methylguanine‐DNA methyltransferase (MGMT) promoter methylation and low MGMT‐encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomideCancer, 2012
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsNeuro-Oncology, 2011
- MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951Journal of Clinical Oncology, 2009
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and OligodendrogliomasThe American Journal of Pathology, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Environmental risk factors for primary malignant brain tumors: A reviewJournal of Neuro-Oncology, 1993